Ming‐Chung Wang

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

Sung‐Nan Pei, Chien‐Hung Chen, Chuan–Mo Lee et al. · Annals of Hematology · 2009 · 211 citations

Life Sciences, Immunology, Infectious Diseases +17

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 137 citations · Full text

Medicine, Immunology, Pharmacology +11

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy

Sung‐Nan Pei, Ming‐Chun Ma, Ming‐Chung Wang et al. · Annals of Hematology · 2012 · 91 citations

Life Sciences, Immunology, Oncology +12

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy et al. · The Lancet Haematology · 2023 · 67 citations

Medicine, Pharmacology, Pharmacotherapy +10